Abstract
The introduction of multimodal therapeutic strategies has improved the outcome of patients with peritoneal metastasis (PM). However, therapy response assessment in PM remains a challenge in modern oncology. Despite the progress in molecular techniques, the conventional morphological investigation in histology remains the gold standard in diagnosing malignancies and assessing therapy response. In 2016, a group of pathologists in Europe has proposed a novel regression grading score for therapy response assessment in peritoneal metastasis, the Peritoneal Regression Grading Score (PRGS). PRGS has moderate to good/substantial interobserver variability and good to excellent/almost perfect intraobserver variability for the assessment of response to treatment of PM. PRGS can be used by younger pathologists without loss of accuracy. The PRGS allows the comparison of therapy response in different research studies and with different primary tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, et al. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127:506–10.
Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.
Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol. 2015;137:223–8.
Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65:284–98.
Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH. Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction colorectal peritoneal carcinomatosis: an experimental study. Ann Surg Oncol. 2012;19:475–82.
Saini A, Pershad Y, Albadawi H, Kuo M, Alzubaidi S, Naidu S, Knuttinen MG, Oklu R. Liquid biopsy in gastrointestinal cancers. Diagnostics (Basel). 2018;8(4):E75. https://doi.org/10.3390/diagnostics8040075. Review.
Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch. 2018;472(2):175–86. https://doi.org/10.1007/s00428-017-2232-x. Epub 16 Sept 2017. Review.
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.
Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521–30.
Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–40; discussion 741–2.
Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.
Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344–51.
Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. ScientificWorldJournal. 2013;2013:978394.
Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21:2608–14.
Graversen M, Fristrup C, Kristensen TK, Larsen TR, Pfeiffer P, Mortensen MB, Detlefsen S. Detection of free intraperitoneal tumour cells in peritoneal lavage fluid from patients with peritoneal metastasis before and after treatment with pressurised intraperitoneal aerosol chemotherapy (PIPAC). J Clin Pathol. 2019;72:368–72. pii: jclinpath-2018-205683. https://doi.org/10.1136/jclinpath-2018-205683.
Solass W, Sempoux C, Carr N, Bibeau F, Neureiter D, Jäger T, Di Caterino T, Brunel C, Klieser E, Fristrup C, Mortensen MB, Detlefsen S. Reproducibility of the Peritoneal Regression Grading Score (PRGS) for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019;74:1014. https://doi.org/10.1111/his.13829.
Böhm S, Faruqi A, Said I, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33:2457–63.
Said I, Böhm S, Beasley J, et al. The chemotherapy response score (crs): interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in tuboovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2017;36:172–9.
Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. https://doi.org/10.3389/fonc.2013.00262. Review.
Solass W, Sempoux C, Detlefsen S, et al. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1(2):99–107. https://doi.org/10.1515/pp-2016-0011. Retrieved 1 Mar 2019.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Solass, W. (2020). Peritoneal Regression Grading Score (PRGS) for Therapy Response Assessment in Peritoneal Metastasis. In: Glehen, O., Bhatt, A. (eds) Pathology of Peritoneal Metastases. Springer, Singapore. https://doi.org/10.1007/978-981-15-3773-8_9
Download citation
DOI: https://doi.org/10.1007/978-981-15-3773-8_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-3772-1
Online ISBN: 978-981-15-3773-8
eBook Packages: MedicineMedicine (R0)